GSK plc (NYSE:GSK) Stock Holdings Boosted by Callodine Capital Management LP

Callodine Capital Management LP boosted its position in GSK plc (NYSE:GSK) by 15.7% in the fourth quarter, HoldingsChannel.com reports. The institutional investor owned 700,000 shares of the pharmaceutical company’s stock after purchasing an additional 95,000 shares during the period. GSK makes up approximately 4.9% of Callodine Capital Management LP’s holdings, making the stock its 5th largest holding. Callodine Capital Management LP’s holdings in GSK were worth $23,674,000 at the end of the most recent reporting period.

Several other hedge funds have also recently made changes to their positions in GSK. Dodge & Cox increased its holdings in GSK by 0.5% in the 4th quarter. Dodge & Cox now owns 68,440,912 shares of the pharmaceutical company’s stock worth $2,314,672,000 after acquiring an additional 353,749 shares during the last quarter. FMR LLC increased its stake in shares of GSK by 82.1% in the fourth quarter. FMR LLC now owns 52,823,032 shares of the pharmaceutical company’s stock worth $1,786,475,000 after purchasing an additional 23,814,104 shares in the last quarter. Primecap Management Co. CA raised its position in shares of GSK by 70.1% in the fourth quarter. Primecap Management Co. CA now owns 25,261,660 shares of the pharmaceutical company’s stock valued at $854,349,000 after purchasing an additional 10,407,905 shares during the period. Fisher Asset Management LLC lifted its stake in shares of GSK by 1.4% during the 4th quarter. Fisher Asset Management LLC now owns 18,836,797 shares of the pharmaceutical company’s stock valued at $637,061,000 after buying an additional 259,867 shares in the last quarter. Finally, Mondrian Investment Partners LTD boosted its holdings in GSK by 17.6% in the 4th quarter. Mondrian Investment Partners LTD now owns 5,838,384 shares of the pharmaceutical company’s stock worth $205,920,000 after buying an additional 874,004 shares during the period. 15.74% of the stock is currently owned by institutional investors.

GSK Price Performance

GSK stock opened at $35.92 on Friday. The business has a 50-day simple moving average of $37.44 and a 200 day simple moving average of $36.14. GSK plc has a 52 week low of $31.72 and a 52 week high of $45.93. The stock has a market cap of $74.10 billion, a price-to-earnings ratio of 22.59, a PEG ratio of 1.12 and a beta of 0.56. The company has a quick ratio of 0.52, a current ratio of 0.78 and a debt-to-equity ratio of 1.12.

GSK (NYSE:GSK) last issued its quarterly earnings data on Wednesday, February 5th. The pharmaceutical company reported $0.59 EPS for the quarter, topping the consensus estimate of $0.44 by $0.15. GSK had a return on equity of 48.59% and a net margin of 8.13%. On average, research analysts forecast that GSK plc will post 4.14 earnings per share for the current fiscal year.

GSK Increases Dividend

The business also recently declared a quarterly dividend, which was paid on Thursday, April 10th. Stockholders of record on Friday, February 21st were issued a $0.3932 dividend. This is a positive change from GSK’s previous quarterly dividend of $0.39. The ex-dividend date of this dividend was Friday, February 21st. This represents a $1.57 dividend on an annualized basis and a dividend yield of 4.38%. GSK’s dividend payout ratio is presently 100.63%.

Analyst Ratings Changes

Several equities research analysts have issued reports on GSK shares. StockNews.com downgraded GSK from a “strong-buy” rating to a “buy” rating in a research report on Wednesday. BNP Paribas initiated coverage on GSK in a research note on Tuesday. They issued a “neutral” rating and a $35.25 target price for the company. Finally, Morgan Stanley assumed coverage on GSK in a report on Wednesday, February 12th. They set an “equal weight” rating for the company. Eight research analysts have rated the stock with a hold rating, one has given a buy rating and three have issued a strong buy rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $40.58.

About GSK

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.